Clinical Trials Logo

Filter by:
NCT ID: NCT05409378 Withdrawn - Clinical trials for Aortic Regurgitation

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

RIVAL - AR EFS
Start date: July 8, 2022
Phase: N/A
Study type: Interventional

To evaluate the safety and performance of The Meridian® TAVR Valve in patients with severe aortic regurgitation who present at high risk for aortic valve replacement surgery.

NCT ID: NCT05408923 Withdrawn - Clinical trials for Lumbar Spine Degeneration

Randomized Controlled Trial Comparing Irrisept Versus Normal Saline for Wound Irrigation After Posterior Spine Surgery

Irrisept
Start date: July 2022
Phase: Phase 4
Study type: Interventional

To compare post-operative wound complications in patients randomized to normal saline versus Irrisept solution and any other adverse reactions from the solution.

NCT ID: NCT05405192 Withdrawn - Clinical trials for Gestational Trophoblastic Neoplasia

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if Dostarlimab is an effective treatment for Gestational Trophoblastic Neoplasia (GTN).

NCT ID: NCT05403528 Withdrawn - Healthy Clinical Trials

Technology/Digital Media Use and Children's Word Learning Development

Start date: April 7, 2022
Phase: N/A
Study type: Interventional

The goal of this work is to address increasing concerns about young children's digital media exposure and language outcomes by testing how the times course of word learning unfolds in digital environments and the cascading impact of digital media on vocabulary outcomes. The findings will have important implications for understanding when and where optimal word learning from media can occur.

NCT ID: NCT05400577 Withdrawn - Clinical trials for Non-Small Cell Lung Cancer

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Start date: July 13, 2022
Phase: Phase 2
Study type: Interventional

This is a single arm study, conducted at two centers, of neoadjuvant sotorasib in treatment naïve patients with stage Ib-IIIa NSCLC. The study will accrue 25 patients in all. Patients must have been deemed surgically resectable and physiologically fit for surgery by a thoracic surgeon prior to enrollment.

NCT ID: NCT05399550 Withdrawn - Clinical trials for Acute Ischemic Stroke

Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema

Start date: June 22, 2022
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing Malignant Cerebral Edema (MCE)

NCT ID: NCT05395039 Withdrawn - Depression Clinical Trials

Virtual Communication in the Hospital: Impact on Patients and Surrogates

VCHIPS
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This is a pilot study of scheduled video/audio conferences by clinical navigators on the experience of surrogate decision makers for hospitalized older adults with Alzheimer's disease (AD), delirium, and other causes of cognitive impairment. The purpose of this study is to learn more about the experiences of surrogate decision makers of hospitalized older adults when they cannot be physically present with the patient in the hospital. We will conduct a randomized pilot study of virtual visits to connect the surrogate decision makers of incapacitated, hospitalized older adults with AD, delirium, and related causes of cognitive impairment with the patient and clinicians.

NCT ID: NCT05393089 Withdrawn - Presbyopia Clinical Trials

Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia

ARIES
Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

Presbyopia is a condition in which the eye exhibits a diminished ability to focus on near objects with increasing age. This study will assess the safety and exploratory efficacy of AGN-190584 is in treating participants with pseudophakic presbyopia. AGN-190584 is approved (in the United States) for use in adults with presbyopia (including those who are pseudophakic) and this study is being conducted to better understand the safety and efficacy in the pseudophakic presbyopia population. This study is double-masked meaning that neither the participants nor the study doctors will know who will be given AGN-190584 and who will be given vehicle (does not contain treatment drug). Study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to vehicle. Approximately 150 participants aged 40-80 years with pseudophakic presbyopia will be enrolled in approximately 30 sites in the US. Participants will receive eye drops of AGN-190584 or vehicle once daily in the morning in each eye for 14 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study. The effect of the treatment will be evaluated by medical assessments, checking for side effects and completing questionnaires.

NCT ID: NCT05390177 Withdrawn - Healthy Aging Clinical Trials

Memory for Health Research Findings

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This experiment tests young (ages 18-35) and older adult (ages 60-80) participants. Participants will watch a brief video, will complete a memory task, and will complete measures about their beliefs.

NCT ID: NCT05389488 Withdrawn - Ischemic Stroke Clinical Trials

OsciPulse D-dimer Efficacy Trial

Start date: December 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of the OsciPulse System in reducing serum d-dimer levels in hospitalized ischemic stroke patients.